What is the appropriate management for a patient with ulcerative colitis who received infliximab (Remicade) yesterday and now presents with a few episodes of diarrhea and a small amount of rectal bleeding?

Management of Breakthrough Symptoms in UC Patient on Infliximab

This patient requires immediate clinical assessment to determine if these symptoms represent true disease flare, infection (particularly C. difficile), or expected post-infusion variability, with stool studies and clinical severity scoring as the first steps before any treatment escalation.

Immediate Assessment Required

The timing of symptoms (one day post-infusion) is critical. This presentation demands urgent evaluation before assuming treatment failure:

Rule Out Infection First

• Send stool studies immediately for C. difficile, bacterial pathogens, and CMV (if severe) 1
• C. difficile infection can mimic UC flare and occurred in the case literature even during biologic therapy 2
• Do not escalate immunosuppression until infection is excluded

Assess True Disease Severity

Determine if this represents:

• Mild breakthrough symptoms (few episodes, small bleeding) vs. moderate-severe activity
• Use objective measures: stool frequency, visible blood amount, systemic symptoms, vital signs
• Check inflammatory markers (CRP, fecal calprotectin if available)

Clinical Decision Algorithm

If Infection is Excluded:

For Mild Symptoms (Current Presentation):

• Add rectal mesalamine therapy as bridge treatment 3
  • This addresses distal inflammation effectively
  • Can be combined with oral 5-ASA if not already on it
• Continue scheduled infliximab maintenance
• Reassess in 2-4 weeks

For Moderate-Severe Symptoms:

• Consider infliximab dose optimization 4, 5
  • Check infliximab trough levels if available
  • Loss of response occurs in ~10% annually with infliximab 5
  • Accelerated dosing (additional infusions at weeks 1-2) may be beneficial 2, 4
• If inadequate response within 2 weeks, escalate to oral corticosteroids 1

Critical Pitfalls to Avoid

1. Do not assume treatment failure after single infusion - pharmacokinetics show variable early response 6
2. Do not add corticosteroids without infection workup - this increases risk if C. difficile present 2
3. Do not continue 5-ASA alone if moderate-severe disease - requires advanced therapy optimization 7

If True Infliximab Failure

Based on FDA label and guidelines 6, 7:

• Infliximab demonstrated 69% clinical response at week 8 in moderate-severe UC
• If confirmed loss of response despite optimization:
  • Switch to alternative advanced therapy (vedolizumab, ustekinumab, JAK inhibitors, or other IL-23 antagonists)
  • Strong recommendation for switching rather than continuing failed therapy 7

Monitoring Strategy

• Objective assessment required - do not rely on symptoms alone 8
• Endoscopy if symptoms persist beyond 2-4 weeks despite treatment adjustment
• Serial inflammatory markers to guide therapy
• Consider therapeutic drug monitoring for infliximab levels and antibodies 4

Special Consideration

The case literature documents that "all that bleeds is not infliximab-refractory" 9 - other causes including infection, medication effects, and hemorrhoids must be excluded before declaring biologic failure.